NEFL and amyotrophic lateral sclerosis: The NFL peptide PRM might be used as reference method for NFL immunoassays Nevertheless, future studies must clarify their clinical value for (differential) diagnosis, monitoring disease progression and treatment response, their changes in the preclinical phase of ALS and whether the peptide level changes are indicative of the parent protein concentration or reflect changes in protein processing.